Literature DB >> 16388494

GB virus C replicates in primary T and B lymphocytes.

Sarah L George1, Dino Varmaz, Jack T Stapleton.   

Abstract

GB virus C (GBV-C) infection is common in humans and may persist for decades, although most infected persons clear the virus and subsequently develop antibodies to the envelope glycoprotein. GBV-C replicates in peripheral blood mononuclear cells (PBMCs) and CD4(+) T lymphocytes in vitro, and depletion of CD4(+) T lymphocytes has been proposed as the reason for clearance of GBV-C among persons positive for human immunodeficiency virus. We identified GBV-C RNA in purified CD4(+) and CD8(+) T lymphocytes and CD19(+) B lymphocytes removed ex vivo from infected donors and found that GBV-C replicated in vitro in these PBMC subsets, suggesting that GBV-C is a panlymphotropic virus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16388494     DOI: 10.1086/499435

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  46 in total

Review 1.  Tropism of human pegivirus (formerly known as GB virus C/hepatitis G virus) and host immunomodulation: insights into a highly successful viral infection.

Authors:  Ernest T Chivero; Jack T Stapleton
Journal:  J Gen Virol       Date:  2015-02-09       Impact factor: 3.891

2.  Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Authors:  Angelo Fama; Jinhua Xiang; Brian K Link; Cristine Allmer; Donna Klinzman; Andrew L Feldman; Grzegorz S Nowakowski; Mark Liebow; Melissa C Larson; Matthew J Maurer; Stephen M Ansell; Anne J Novak; Yan W Asmann; Susan L Slager; Timothy G Call; Thomas M Habermann; James R Cerhan; Jack T Stapleton
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

3.  GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals.

Authors:  Jack T Stapleton; Jeffrey A Martinson; Donna Klinzman; Jinhua Xiang; Seema N Desai; Alan Landay
Journal:  AIDS       Date:  2013-07-17       Impact factor: 4.177

4.  GBV-C infection and risk of NHL among U.S. adults.

Authors:  Cindy M Chang; Jack T Stapleton; Donna Klinzman; James H McLinden; Mark P Purdue; Hormuzd A Katki; Eric A Engels
Journal:  Cancer Res       Date:  2014-08-12       Impact factor: 12.701

5.  Transmission of GB virus type C via transfusion in a cohort of HIV-infected patients.

Authors:  Farnaz Vahidnia; M Petersen; G Rutherford; M Busch; S Assmann; J T Stapleton; B Custer
Journal:  J Infect Dis       Date:  2012-03-20       Impact factor: 5.226

6.  Characterization of a peptide domain within the GB virus C envelope glycoprotein (E2) that inhibits HIV replication.

Authors:  Jinhua Xiang; James H McLinden; Thomas M Kaufman; Emma L Mohr; Nirjal Bhattarai; Qing Chang; Jack T Stapleton
Journal:  Virology       Date:  2012-05-16       Impact factor: 3.616

7.  GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Thomas M Kaufman; Jack T Stapleton
Journal:  J Immunol       Date:  2012-07-27       Impact factor: 5.422

8.  Viruses within the Flaviviridae decrease CD4 expression and inhibit HIV replication in human CD4+ cells.

Authors:  Jinhua Xiang; James H McLinden; Robert A Rydze; Qing Chang; Thomas M Kaufman; Donna Klinzman; Jack T Stapleton
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Chimpanzee GB virus C and GB virus A E2 envelope glycoproteins contain a peptide motif that inhibits human immunodeficiency virus type 1 replication in human CD4⁺ T-cells.

Authors:  James H McLinden; Jack T Stapleton; Donna Klinzman; Krishna K Murthy; Qing Chang; Thomas M Kaufman; Nirjal Bhattarai; Jinhua Xiang
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

10.  GB virus C particles inhibit T cell activation via envelope E2 protein-mediated inhibition of TCR signaling.

Authors:  Nirjal Bhattarai; James H McLinden; Jinhua Xiang; Alan L Landay; Ernest T Chivero; Jack T Stapleton
Journal:  J Immunol       Date:  2013-05-17       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.